4-phenylbutyric acid has been researched along with Neoplasms in 9 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a phase I trial to determine the minimal effective dose and optimal dose schedule for 5-azacytidine (5-AC) in combination with sodium phenylbutyrate in patients with refractory solid tumors." | 2.74 | A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. ( Ambinder, RF; Baker, SD; Carducci, MA; Donehower, RC; Gilbert, J; Gore, S; Herman, JG; Jiemjit, A; Lin, J; Rudek, MA; Zhao, M; Zwiebel, JA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Saito, Y | 1 |
| Friedman, JM | 1 |
| Chihara, Y | 1 |
| Egger, G | 2 |
| Chuang, JC | 1 |
| Liang, G | 1 |
| Lin, J | 1 |
| Gilbert, J | 2 |
| Rudek, MA | 1 |
| Zwiebel, JA | 1 |
| Gore, S | 1 |
| Jiemjit, A | 1 |
| Zhao, M | 1 |
| Baker, SD | 1 |
| Ambinder, RF | 1 |
| Herman, JG | 1 |
| Donehower, RC | 2 |
| Carducci, MA | 2 |
| PIACENTINI, G | 1 |
| PERISCO, L | 1 |
| Stepulak, A | 1 |
| Stryjecka-Zimmer, M | 1 |
| Kupisz, K | 1 |
| Polberg, K | 1 |
| Aparicio, AM | 1 |
| Escobar, SG | 1 |
| Jones, PA | 1 |
| Ozcan, U | 1 |
| Ozcan, L | 1 |
| Yilmaz, E | 1 |
| Düvel, K | 1 |
| Sahin, M | 1 |
| Manning, BD | 1 |
| Hotamisligil, GS | 1 |
| Warrell, RP | 1 |
| Bowling, MK | 1 |
| Noe, D | 1 |
| Eisenberger, MA | 1 |
| Sinibaldi, V | 1 |
| Zabelina, Y | 1 |
| Chen, TL | 1 |
| Grochow, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors[NCT00005639] | Phase 1 | 34 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for 4-phenylbutyric acid and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].
Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Ac | 2005 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Dr | 1999 |
2 trials available for 4-phenylbutyric acid and Neoplasms
| Article | Year |
|---|---|
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Mod | 2009 |
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Disorders of Excessive Somnolenc | 2001 |
4 other studies available for 4-phenylbutyric acid and Neoplasms
| Article | Year |
|---|---|
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Calcium-Binding Proteins; Cell Line, Tumor; Decitabine; EGF Fami | 2009 |
[p-(Bis-2-chloroethylamino)-phenylbutyric acid (CB 1348) in oncological therapy].
Topics: Chlorambucil; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Phenylbutyrates | 1960 |
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tum | 2007 |
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Child, P | 2008 |